Clinical trials: Otorhinolaryngologic Neoplasms
Pulsed Radiofrequency, Super Voltage Pulsed Radiofrequency
Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain
The aim of this study is to evaluate the safety and efficacy of supervoltage pulsed radiofrequency glossopharyngeal nerve therapy versus standard pulsed radiofrequency in reduction of oropharyngeal cancer pain, through Visual…
- Conditions
- Pulsed Radiofrequency, Super Voltage Pulsed Radiofrequency, Glossopharyngeal Nerve, Oropharyngeal Cancer
- Trial name
- NCT06121102
- Testing
- Supervoltage pulsed radiofrequency glossopharyngeal nerve block, Standard voltage pulsed radiofrequency glossopharyngeal nerve block
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute, Egypt
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.
- Trial name
- NCT04978012
- Testing
- Fluzoparib and Camrelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Brain Necrosis
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
It is hypothesized that excessive generation of free radicals involves in the pathogenesis of radiation-induced brain necrosis. This study therefore evaluated the effect of free radical scavenger, edaravone, on radiation-induced…
- Trial name
- NCT01865201
- Testing
- Edaravone, Common fundamental management
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Pain, Postoperative, Cancer of Larynx
Efficacy of Adding Dexmedetomidine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy Surgery
The cervical plexus block (CPB) is one such block used to provide effective anesthesia and analgesia for surgery in the head and neck region.
- Trial name
- NCT05814744
- Testing
- dexmedetomidine, bupivacaine 0.25%, Thyroidectomy Surgery
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute, Egypt
Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT07101744
- Testing
- Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to verify that induction gemcitabine and cisplatin plus intensity-modulated radiotherapy (IMRT) is non-inferior to concurrent weekly cisplatin plus IMRT for patients with locoregionally advanced…
- Trial name
- NCT02460887
- Testing
- Gemcitabine, cisplatin, Intensity-modulated Radiotherapy
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Nasopharyngeal Carcinoma, De-escalation Therapy
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06675214
- Testing
- Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03854838
- Testing
- Tolipalimab, Reirradiation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Human Papilloma Virus, Cervical Cancer
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
The project aims to increase HPV vaccination and cervical cancer screening through a web-based mobile health education program called, Wheel of Wellness (WoW) and a brief negotiated interview (BNI).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer
- Trial name
- NCT03346915
- Testing
- WoW and BNI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharynx Cancer
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent…
- Trial name
- NCT06611826
- Testing
- GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Neurofibromatosis 1 and 2 (NF1 and NF2)
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
Patients with clinically confirmed neurofibromatosis type 1 (NF1) or neurofibromatosis type 2 (NF2) or a known neurofibromatosis (NF) mutation aged 5 years and above will be eligible to participate and will be recruited from the…
- Trial name
- NCT03672838
- Testing
- hand-held dynamometer
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NYU Langone Health
Human Papillomavirus (HPV), Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx
AMG 319 in HPV Positive and Negative HNSCC
The purpose of this study is to determine whether a drug called AMG 319 has an effect on a patient's own immune response to head and neck cancer squamous cell carcinoma (HNSCC).
- Trial name
- NCT02540928
- Testing
- AMG 319 hydrate
- Where
- 5 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Cancer Research UK
Nasopharyngeal Neoplasms, Blood Cell Count
Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
RATIONALE 1. In patients with nasopharyngeal carcinoma, there is sometimes a discrepancy between actual clinical outcome and TNM stages because it is an anatomy-based system in which functional factors are not concerned. 2.
- Conditions
- Nasopharyngeal Neoplasms, Blood Cell Count, Neoplasm Staging, Prognosis
- Trial name
- NCT02211677
- Where
- 6 sites in China
- Volunteers
- 720 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancers
Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
This is a open,randomized phase II trial comparing effectiveness and safety of local use of rhGM-CSF and Compound Vitamin B12 to Compound Vitamin B12 solution alone treating oral mucositis in primary nasopharyngeal cancer.
- Trial name
- NCT01806272
- Testing
- rhGM-CSF, Compound Vitamin B12
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Wei LUO
Oropharyngeal Cancer
PEARL PET-based Adaptive Radiotherapy Clinical Trial
The PEARL study will recruit approximately 50 patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) who are about to undergo primary treatment with concurrent chemo-radiation from South…
- Trial name
- PEARL (NCT03935672)
- Testing
- PET-CT scans, Outlining the biological GTVs (bGTV_P and bGTV_iP), Blood samples for cell-free DNA analysis
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Velindre NHS Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.